Literature DB >> 18613261

Diagnostic codes for sudden cardiac death and ventricular arrhythmia functioned poorly to identify outpatient events in EPIC's General Practice Research Database.

Sean Hennessy1, Charles E Leonard, Cristin M Palumbo, Warren B Bilker, Craig Newcomb, Stephen E Kimmel.   

Abstract

PURPOSE: To examine the validity of OXMIS/Read diagnoses of hospitalization for sudden cardiac death and ventricular arrhythmia (SD/VA) for use in studies of arrhythmogenic effects of outpatient medications in the General Practice Research Database (GPRD).
METHODS: We identified putative occurrences of hospitalization for SD/VA in patients receiving outpatient prescriptions for cisapride, domperidone, or metoclopramide. We then administered a questionnaire to general practitioners (GPs) caring for these patients, requested hospital discharge consult letters, and examined the positive predictive value (PPV) of diagnostic codes in identifying outpatient events precipitating hospitalization.
RESULTS: We identified 84 putative events, 38 (45%) of which occurred in patients cared for by GPs participating in the follow-up scheme. Thirty of 38 questionnaires (79%) were completed. The PPV for the occurrence of any SD/VA was 93% (95% CI, 78-99%). However, the PPV for SD/VA occurrence in an outpatient setting precipitating a hospitalization was only 23% (95% CI, 10-42%). The majority of inpatient diagnostic codes reflected events occurring after hospital admission, not precipitating it.
CONCLUSIONS: While computerized codes for SD/VA agreed well with physician diagnosis, they operated poorly to identify events occurring in an outpatient setting. Studies of SD/VA in the GPRD should verify events on a case-by-case basis. Copyright (c) 2008 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18613261      PMCID: PMC2596275          DOI: 10.1002/pds.1632

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN: 1053-8569            Impact factor:   2.890


  11 in total

1.  State-specific mortality from sudden cardiac death--United States, 1999.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2002-02-15       Impact factor: 17.586

2.  Prolongation of the QT interval and cardiac arrhythmias associated with cisapride: limitations of the pharmacoepidemiological studies conducted and proposals for the future.

Authors:  Deborah Layton; Cheryl Key; Saad A W Shakir
Journal:  Pharmacoepidemiol Drug Saf       Date:  2003 Jan-Feb       Impact factor: 2.890

3.  Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions.

Authors:  Diane K Wysowski; Lynette Swartz
Journal:  Arch Intern Med       Date:  2005-06-27

4.  Use of the UK General Practice Research Database for pharmacoepidemiology.

Authors:  L A García Rodríguez; S Pérez Gutthann
Journal:  Br J Clin Pharmacol       Date:  1998-05       Impact factor: 4.335

5.  Risk of ventricular arrhythmias associated with nonsedating antihistamine drugs.

Authors:  F J de Abajo; L A Rodríguez
Journal:  Br J Clin Pharmacol       Date:  1999-03       Impact factor: 4.335

6.  Antipsychotics and the risk of sudden cardiac death.

Authors:  W A Ray; S Meredith; P B Thapa; K G Meador; K Hall; K T Murray
Journal:  Arch Gen Psychiatry       Date:  2001-12

7.  Cardiac arrest and ventricular arrhythmia in patients taking antipsychotic drugs: cohort study using administrative data.

Authors:  Sean Hennessy; Warren B Bilker; Jill S Knauss; David J Margolis; Stephen E Kimmel; Robert F Reynolds; Dale B Glasser; Mary F Morrison; Brian L Strom
Journal:  BMJ       Date:  2002-11-09

8.  Serious ventricular arrhythmias among users of cisapride and other QT-prolonging agents in the United States.

Authors:  Cheryl Enger; Clorinda Cali; Alexander M Walker
Journal:  Pharmacoepidemiol Drug Saf       Date:  2002-09       Impact factor: 2.890

9.  The risk of serious cardiac arrhythmias among cisapride users in the United Kingdom and Canada.

Authors:  A M Walker; P Szneke; L B Weatherby; L W Dicker; L L Lanza; J E Loughlin; C L Yee; N A Dreyer
Journal:  Am J Med       Date:  1999-10       Impact factor: 4.965

10.  Risk of developing life-threatening ventricular arrhythmia associated with tefenadine in comparison with over-the-counter antihistamines, ibuprofen and clemastine.

Authors:  C M Pratt; R P Hertz; B E Ellis; S P Crowell; W Louv; L Moyé
Journal:  Am J Cardiol       Date:  1994-02-15       Impact factor: 2.778

View more
  9 in total

Review 1.  Validity of diagnostic coding within the General Practice Research Database: a systematic review.

Authors:  Nada F Khan; Sian E Harrison; Peter W Rose
Journal:  Br J Gen Pract       Date:  2010-03       Impact factor: 5.386

2.  Should Domperidone be Used as a Galactagogue? Possible Safety Implications for Mother and Child.

Authors:  Luc M Hondeghem; Noël H Logghe
Journal:  Drug Saf       Date:  2017-02       Impact factor: 5.606

3.  A comparison of two algorithms to identify sudden cardiac deaths in computerized databases.

Authors:  Jea Young Min; Carlos G Grijalva; James A Morrow; Christine C Whitmore; Robert E Hawley; Sonal Singh; Richard S Swain; Marie R Griffin
Journal:  Pharmacoepidemiol Drug Saf       Date:  2019-08-07       Impact factor: 2.890

4.  Use of venlafaxine compared with other antidepressants and the risk of sudden cardiac death or near death: a nested case-control study.

Authors:  Carlos Martinez; Themistocles L Assimes; Daniel Mines; Sophie Dell'aniello; Samy Suissa
Journal:  BMJ       Date:  2010-02-05

5.  Validation of diagnostic codes for outpatient-originating sudden cardiac death and ventricular arrhythmia in Medicaid and Medicare claims data.

Authors:  Sean Hennessy; Charles E Leonard; Cristin P Freeman; Rajat Deo; Craig Newcomb; Stephen E Kimmel; Brian L Strom; Warren B Bilker
Journal:  Pharmacoepidemiol Drug Saf       Date:  2010-06       Impact factor: 2.890

6.  Risk of Mortality (including Sudden Cardiac Death) and Major Cardiovascular Events in Users of Olanzapine and Other Antipsychotics: A Study with the General Practice Research Database.

Authors:  Meghan E Jones; Giedra Campbell; Deven Patel; Elizabeth Brunner; Chetan C Shatapathy; Tarita Murray-Thomas; Tjeerd P van Staa; Stephen Motsko
Journal:  Cardiovasc Psychiatry Neurol       Date:  2013-12-14

7.  Risk of mortality (including sudden cardiac death) and major cardiovascular events in atypical and typical antipsychotic users: a study with the general practice research database.

Authors:  Tarita Murray-Thomas; Meghan E Jones; Deven Patel; Elizabeth Brunner; Chetan C Shatapathy; Stephen Motsko; Tjeerd P Van Staa
Journal:  Cardiovasc Psychiatry Neurol       Date:  2013-12-26

8.  QT interval and antidepressant use: a cross sectional study of electronic health records.

Authors:  Victor M Castro; Caitlin C Clements; Shawn N Murphy; Vivian S Gainer; Maurizio Fava; Jeffrey B Weilburg; Jane L Erb; Susanne E Churchill; Isaac S Kohane; Dan V Iosifescu; Jordan W Smoller; Roy H Perlis
Journal:  BMJ       Date:  2013-01-29

9.  Antidepressant use and risk of cardiovascular outcomes in people aged 20 to 64: cohort study using primary care database.

Authors:  Carol Coupland; Trevor Hill; Richard Morriss; Michael Moore; Antony Arthur; Julia Hippisley-Cox
Journal:  BMJ       Date:  2016-03-22
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.